AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6656960 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (60 Gy)
Number of subjects: 174
Study 6656960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy with chemotherapy: methotrexate and 5-fluorouracil)
Number of subjects: 174
Study 6656960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy with chemotherapy)
Number of subjects: 174
Study 31092823 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 1028
Study 31092823 — intervention group
Group type: COMPARATOR
Intervention: Baseline CSP IgG levels
Number of subjects: 1028
Study 31092823 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG magnitude to NANP post-vaccination
Number of subjects: 1028
Study 31092823 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG avidity to C-terminus post-vaccination
Number of subjects: 1028
Study 31092823 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG avidity to C-terminus
Number of subjects: 1028
Study 28648704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicruciate-stabilized implant
Number of subjects: 228
Study 28648704 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized implant
Number of subjects: 228
Study 28648704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AEs)
Number of subjects: 228
Study 28648704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (revisions)
Number of subjects: 228
Study 25889509 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/d L-selenomethionine)
Number of subjects: 1641
Study 25889509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day all rac-α-tocopheryl acetate)
Number of subjects: 1641
Study 25889509 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium combined with Vitamin E
Number of subjects: 1641
Study 25889509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1641
Study 24094658 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 33
Study 24094658 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 33
Study 21292922 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 174
Study 21292922 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 174
Study 21292922 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 174
Study 21292922 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol, Risperidone, Olanzapine
Number of subjects: 174
Study 19303575 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8mg/day
Number of subjects: 10962
Study 19303575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10962
Study 17726586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular ketamine (0.25 mg S-(+)-ketamine/kg body weight in 10 ml 0.9% NaCl)
Number of subjects: 68
Study 17726586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg S-(+)-ketamine/kg body weight)
Number of subjects: 68
Study 17726586 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular bupivacaine (10 ml 0.25% bupivacaine)
Number of subjects: 68
Study 17726586 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml 0.9% NaCl)
Number of subjects: 68
Study 15481068 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen
Number of subjects: 20
Study 15481068 — intervention group
Group type: COMPARATOR
Intervention: Reminiscence therapy
Number of subjects: 20
Study 11578884 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) 25 ng/kg/min
Number of subjects: 40
Study 11578884 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) 50 ng/kg/min
Number of subjects: 40
Study 11578884 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 40
Study 9562230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole 20 mg daily
Number of subjects: 13
Study 9562230 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine alone
Number of subjects: 13
Study 7651057 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteïne (NAC) 3 x 600 mg per day for 5 days, starting 5 or 10 days after Photofrin
Number of subjects: 27
Study 7651057 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteïne (NAC)
Number of subjects: 27
Study 2689182 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg per day orally)
Number of subjects: 0
Study 2689182 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (4 g.m-2 body surface area)
Number of subjects: 0
Study 766724 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxogas gas producing suppositories
Number of subjects: 0
Study 30952672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge)
Number of subjects: 30
Study 30952672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 30
Study 29949271 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step method for shoulder delivery
Number of subjects: 0
Study 29949271 — intervention group
Group type: COMPARATOR
Intervention: One-step method for shoulder delivery
Number of subjects: 0
Study 24699943 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated and culturally attuned CBT group treatment (n = 18)
Number of subjects: 38
Study 24699943 — intervention group
Group type: COMPARATOR
Intervention: Individual counseling services (Control group, n = 20)
Number of subjects: 38
Study 23429358 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose)
Number of subjects: 109
Study 23429358 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 loss-of-function allele carriers (*1/*2 or *3, *2/*2 or *3)
Number of subjects: 109
Study 23429358 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent CV events
Number of subjects: 109
Study 21148683 — intervention group
Group type: EXPERIMENTAL
Intervention: Xevonta Hi 23 (Amembris(®))
Number of subjects: 18
Study 21148683 — intervention group
Group type: EXPERIMENTAL
Intervention: FX dialysers
Number of subjects: 18
Study 21148683 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenium 210 (Purema(®))
Number of subjects: 18
Study 21148683 — intervention group
Group type: EXPERIMENTAL
Intervention: SDS‐PAGE scanning
Number of subjects: 18
Study 19735532 — intervention group
Group type: COMPARATOR
Intervention: Interictal SAT in migraineurs (mean SAT averaged for 1000, 4000, and 8000 Hz)
Number of subjects: 112
Study 19735532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ictal SAT in migraineurs (mean SAT averaged for 1000, 4000, and 8000 Hz)
Number of subjects: 112
Study 16548081 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture including electroacupuncture
Number of subjects: 54
Study 16548081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation with high‐intensity, low‐frequency transcutaneous electrical nerve stimulation
Number of subjects: 54
Study 16548081 — intervention group
Group type: COMPARATOR
Intervention: Low‐intensity (subliminal) high‐frequency transcutaneous electrical nerve stimulation
Number of subjects: 54
Study 15473337 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctures performed at an insertion angle of 50‐60 degrees
Number of subjects: 100
Study 15473337 — intervention group
Group type: COMPARATOR
Intervention: Punctures performed at an insertion angle of 90 degrees
Number of subjects: 100
Study 10969346 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic guided treatment
Number of subjects: 107
Study 10969346 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 107
Study 9428983 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem 500 mg administered intravenously over 30 min
Number of subjects: 38
Study 9428983 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem administered after haemodialysis or in double the dose on haemodialysis days
Number of subjects: 38
Study 7679869 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg) and Hydrochlorothiazide (50 mg) for 3 months
Number of subjects: 14
Study 7679869 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg) for 3 months
Number of subjects: 14
Study 3704892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline sclerotherapy
Number of subjects: 14
Study 3704892 — intervention group
Group type: COMPARATOR
Intervention: Control (drains left in place)
Number of subjects: 14
Study 31848562 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbead enrichment technique using an optoelectrokinetic platform with dual biomarkers (lipocalin 1 and vascular endothelial growth factor) for screening DR
Number of subjects: 24
Study 31848562 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration thresholds of LCN1 and VEGF for indicating proliferative DR
Number of subjects: 24
Study 29194772 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1 mg/kg
Number of subjects: 6
Study 29194772 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 2 mg/kg
Number of subjects: 6
Study 29194772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Aspirin + Clopidogrel)
Number of subjects: 6
Study 29194772 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study 27473139 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg daily
Number of subjects: 43
Study 27473139 — intervention group
Group type: COMPARATOR
Intervention: Interferon β-1b (IFN‐β‐1b) 250 μg subcutaneous every other day
Number of subjects: 43
Study 24093828 — intervention group
Group type: EXPERIMENTAL
Intervention: CyberSenga Internet-based program (five lessons + booster)
Number of subjects: 366
Study 24093828 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 366
Study 21890236 — intervention group
Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 64
Study 21890236 — intervention group
Group type: COMPARATOR
Intervention: In-office care
Number of subjects: 64
Study 21890236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 19815651 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (70 mg/m² on days 1, 8, and 15) combined with carboplatin (AUC = 6 on day 1)
Number of subjects: 82
Study 19815651 — intervention group
Group type: COMPARATOR
Intervention: Standard paclitaxel (200 mg/m² on day 1) combined with carboplatin (AUC = 6 on day 1)
Number of subjects: 82
Study 19101902 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone 1% ointment
Number of subjects: 70
Study 19101902 — intervention group
Group type: COMPARATOR
Intervention: Water-based gel (control)
Number of subjects: 70
Study 15687421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (individual, routine, preventive, outpatient visit with trained primary care physicians)
Number of subjects: 226
Study 15687421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 226
Study 15687421 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual verbal encouragement and routine visits)
Number of subjects: 226
Study 15687421 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study 11837952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light (2,700 lux)
Number of subjects: 54
Study 11837952 — intervention group
Group type: COMPARATOR
Intervention: Dim red light placebo (0.1 lux)
Number of subjects: 54
Study 10084064 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low molecular weight heparin (OP 2000)
Number of subjects: 120
Study 10084064 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 120
Study 7486089 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 7.5 group (3 mL 1.5% lidocaine containing 7.5 micrograms epinephrine)
Number of subjects: 80
Study 7486089 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 15 group (3 mL 1.5% lidocaine containing 15 micrograms epinephrine)
Number of subjects: 80
Study 7486089 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 22.5 group (3 mL 1.5% lidocaine containing 22.5 micrograms epinephrine)
Number of subjects: 80
Study 7486089 — intervention group
Group type: COMPARATOR
Intervention: Saline group (3 mL normal saline)
Number of subjects: 80
Study 2256443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol Retard
Number of subjects: 0
Study 2256443 — intervention group
Group type: COMPARATOR
Intervention: Trimonil Retard
Number of subjects: 0
Study 399436 — intervention group
Group type: EXPERIMENTAL
Intervention: Coccinia indica preparation (experimental group)
Number of subjects: 32
Study 399436 — intervention group
Group type: COMPARATOR
Intervention: Dummy group (control group)
Number of subjects: 32
Study 31567576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-warming blanket
Number of subjects: 112
Study 31567576 — intervention group
Group type: COMPARATOR
Intervention: Forced-air-warming blanket
Number of subjects: 112
Study 27327849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (sugar-free gum every 2 hours for 20 minutes from the end of drinking 2 L of PEG to the beginning of colonoscopy)
Number of subjects: 300
Study 27327849 — intervention group
Group type: COMPARATOR
Intervention: Control (2 L of PEG before colonoscopy)
Number of subjects: 300
Study 27327849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 300
Study 27327849 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study 25886781 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS-MITOS system
Number of subjects: 200
Study 23677743 — intervention group
Group type: EXPERIMENTAL
Intervention: Finely crushed ORF tablets
Number of subjects: 30
Study 23677743 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarsely crushed ORF tablets
Number of subjects: 30
Study 23677743 — intervention group
Group type: COMPARATOR
Intervention: Finely crushed OC tablets
Number of subjects: 30
Study 23677743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tolerability (ORF vs OC)
Number of subjects: 30
Study 23677743 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety profile
Number of subjects: 30
Study 21437161 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol-loaded stents
Number of subjects: 41
Study 21437161 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (Control)
Number of subjects: 41
Study 20137493 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 20137493 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy without antibiotic
Number of subjects: 0
Study 20137493 — intervention group
Group type: EXPERIMENTAL
Intervention: CWDB and wide-type bacteria stimulation
Number of subjects: 0
Study 20137493 — intervention group
Group type: COMPARATOR
Intervention: Control group (chronic tonsillitis patients)
Number of subjects: 0
Study 17298307 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage (Group B)
Number of subjects: 100
Study 17298307 — intervention group
Group type: COMPARATOR
Intervention: No suction drainage (Group A)
Number of subjects: 100
Study 15210458 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 15210458 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 15210458 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall costs comparison
Number of subjects: 0
Study 11426771 — intervention group
Group type: EXPERIMENTAL
Intervention: Colforsin treatment (0.5 microg.kg(‐1).min(‐1) for 6 hours)
Number of subjects: 29
Study 11426771 — intervention group
Group type: COMPARATOR
Intervention: No colforsin treatment (control)
Number of subjects: 29
Study 9714133 — intervention group
Group type: EXPERIMENTAL
Intervention: APOA4-2 allele carriers
Number of subjects: 67
Study 9714133 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP-I diet
Number of subjects: 67
Study 9714133 — intervention group
Group type: EXPERIMENTAL
Intervention: A/A individuals after dietary intervention
Number of subjects: 67
Study 9714133 — intervention group
Group type: EXPERIMENTAL
Intervention: APOA4-360-2 allele
Number of subjects: 67
Study 9714133 — intervention group
Group type: EXPERIMENTAL
Intervention: APOA4-347-T allele
Number of subjects: 67
Study 8283157 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2002
Study 8283157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2002
Study 2597599 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (three tablets/day) for six months (Group A)
Number of subjects: 50
Study 2597599 — intervention group
Group type: COMPARATOR
Intervention: Dietary measures only (Group B)
Number of subjects: 50
Study 2597599 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex in NIDDM patients (Group A)
Number of subjects: 50
Study 5570647 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone administration alongside methyldopa
Number of subjects: 0
Study 5570647 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa alone
Number of subjects: 0
Study 30784008 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible Narcotrend (NT) monitoring
Number of subjects: 245
Study 30784008 — intervention group
Group type: COMPARATOR
Intervention: Blinded Narcotrend (NT) monitoring
Number of subjects: 245
Study 30784008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study 30260990 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 27
Study 30260990 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 28723749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing group (femoral canal sealed with autogenous bone and cement)
Number of subjects: 120
Study 28723749 — intervention group
Group type: COMPARATOR
Intervention: Control group (femoral hole left open)
Number of subjects: 120
Study 26549958 — intervention group
Group type: EXPERIMENTAL
Intervention: Naikan therapy (2 hours daily, 5 days a week for 4 weeks)
Number of subjects: 235
Study 26549958 — intervention group
Group type: COMPARATOR
Intervention: Routine medication and inpatient rehabilitative treatment (Control)
Number of subjects: 235
Study 26549958 — intervention group
Group type: EXPERIMENTAL
Intervention: Naikan therapy
Number of subjects: 235
Study 24246826 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneas from donors 12 to 65 years old
Number of subjects: 176
Study 24246826 — intervention group
Group type: COMPARATOR
Intervention: Corneas from donors 66 to 75 years old
Number of subjects: 176
Study 21261747 — intervention group
Group type: EXPERIMENTAL
Intervention: Kligman-Willis formula (two different versions)
Number of subjects: 34
Study 18722305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-anterolateral approach
Number of subjects: 24
Study 18722305 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-incision approach
Number of subjects: 24
Study 18722305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-posterior approach
Number of subjects: 24
Study 15911663 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-retaining prosthesis
Number of subjects: 80
Study 15911663 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-sacrificing prosthesis
Number of subjects: 80
Study 12881345 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin ophthalmic solution
Number of subjects: 249
Study 12881345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 10392328 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac immediate release (IR) 200 mg
Number of subjects: 187
Study 10392328 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac immediate release (IR) 400 mg
Number of subjects: 187
Study 10392328 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac extended release (ER) 400 mg
Number of subjects: 187
Study 10392328 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac extended release (ER) 1200 mg
Number of subjects: 187
Study 10392328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 10163385 — intervention group
Group type: COMPARATOR
Intervention: Three-person EMS crews for seizures (June)
Number of subjects: 126
Study 10163385 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-person EMS crews for seizures (August)
Number of subjects: 126
Study 10163385 — intervention group
Group type: COMPARATOR
Intervention: Three-person EMS crews for chest pain (June)
Number of subjects: 126
Study 10163385 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-person EMS crews assisted by fire department for chest pain (August)
Number of subjects: 126
Study 12344709 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (mifepristone)
Number of subjects: 120
Study 12344709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6394758 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 10 mg
Number of subjects: 48
Study 6394758 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 25 mg
Number of subjects: 48
Study 6394758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6394758 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 10 mg (after 6 weeks for Group 1)
Number of subjects: 48
Study 6394758 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 25 mg (after 6 weeks for Group 2)
Number of subjects: 48
Study 6394758 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 25 mg (after 6 weeks for Group 3)
Number of subjects: 48
Study 29148346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with enhancements to quality report including biweekly text messages or e‐mails, videos and materials, and tools for discussions with clinicians.
Number of subjects: 245
Study 29148346 — intervention group
Group type: COMPARATOR
Intervention: Control group without enhancements to quality report.
Number of subjects: 245
Study 29318895 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee espresso
Number of subjects: 24
Study 29318895 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee espresso
Number of subjects: 24
Study 29318895 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone
Number of subjects: 24
Study 29318895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hot water)
Number of subjects: 24